Curasight presented promising phase II results from an investigator initiated phase II stu with uTRACE in prostate cancer. About two years later, the company now secures a first license deal for its theranostic platform.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.1 DKK | -8.82% | -9.45% | -48.73% |
Apr. 16 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
Apr. 12 | Curasight A/S Announces Board Changes | CI |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-48.73% | 25.92M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CURAS Stock
- News Curasight A/S
- Curasight Secures Global License Agreement for Utrace in Prostate Cancer